Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9319MR)

This product GTTS-WQ9319MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9319MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15815MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ11631MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ1574MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ1632MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ14202MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ7385MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ11002MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ1527MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW